Zavondemstat (TACH101, QC8222) is a drug which acts as an inhibitor of the enzyme lysine-specific demethylase 4 (KDM4). It is described as a pan-KDM4 inhibitor, being active at all four isoforms KDM4A, KDM4B, KDM4C and KDM4D, which show functional redundancy so older inhibitors selective for just one isoform have failed to be effective. Zavondemstat is being researched for the treatment of certain forms of cancer and is in early stage clinical trials.Chandhasin C, Perabo F, Dai Y, DiMascio L, Mehta RK, Hassan MK, Nyati MK. 245 (PB233): Histone methylation changes of H3K9 and H3K36 in PBMCs as pharmacodynamic biomarkers for Zavondemstat (TACH101), a paninhibitor of KDM4 histone lysine demethylase. European Journal of Cancer 2024; 211: 114763.
References